Background
Inflammatory bowel disease (IBD), with its two clinical manifestations Crohn's Disease (CD) and Ulcerative Colitis (UC), is a widespread and debilitating disease characterized by inflammation and immune cell infiltration and immune-mediated destruction of the gastrointestinal tract [
1]. Activation of the nuclear receptor peroxisome proliferator-activated receptor γ (PPAR γ) has demonstrated efficacy in reducing the severity of IBD by suppressing excessive immunoinflammatory responses [
2‐
4]. In the gut, PPAR γ is highly expressed in epithelial cells, macrophages, and T-cells [
5], and its activation has been shown to repress nuclear factor-κB (NF-κB)-mediated inflammation and promote a regulatory, anti-inflammatory phenotype [
2,
6,
7].
Our laboratory has shown that the deficiency of PPAR γ in hematopoietic and epithelial cells significantly impairs the ability of a naturally occurring PPAR γ ligand, conjugated linoleic acid, to improve inflammatory bowel disease [
2,
8,
9], or inflammation-driven colorectal cancer [
10]. However, it remains unclear how these effects are mediated through macrophages, T cells, epithelial cells, or a combination of cells in the intestinal lamina propria, mesenteric lymph nodes (MLN) and circulating lymphocytes. The role of PPAR γ in epithelial cells was examined by Adachi et al, who found that the deficiency of PPAR γ resulted in significantly worsened disease activity and enhanced levels of pro-inflammatory cytokines interleukin 6 (IL-6) and IL-1β following DSS-induced colitis [
11]. Mohapatra et al also demonstrated that mice lacking PPAR γ in intestinal epithelial cells show upregulated expression of genes in the lysosomal pathway [
12]. Shah and others demonstrated that the deficiency PPAR γ in macrophages also worsens DSS colitis [
13]. However, the importance of T cell PPAR γ in the pathogenesis of IBD is less understood.
The DSS colitis model targets initially epithelial cells and macrophages, but there is a definite T cell involvement at later stages of disease [
14]. Regulatory T cell (Treg) PPARγ is involved in maintaining homeostasis at the gastrointestinal tract [
15,
16] and preventing chronic CD4
+ T cell-induced colitis [
17]. Thus, Treg represent an important target of endogenous and exogenous PPAR γ ligands. The objective of this study was to perform a comprehensive time course analysis of the effect of T cell-specific deletion of PPAR γ on the development of experimental IBD by using a systems approach aimed at examining immune cell distribution, global colonic gene expression and gut immunopathology.
Discussion
Activation of PPAR γ by exogenous administration of synthetic and naturally occurring agonists or through gene therapy has demonstrated pre-clinical efficacy in the prevention and treatment of gut inflammation [
2,
9,
34‐
37]. Accordingly, PPAR γ was proposed as a therapeutic target for gastrointestinal inflammation. The results of a recent randomized, double-blind, placebo controlled study demonstrate that oral administration of rosiglitazone (Avandia), a synthetic PPAR γ ligand of the thiazolidinedione class of anti-diabetic drugs, ameliorates disease activity in human UC patients [
4]. Thus, dissecting the cell specificity of PPAR γ in the prevention and treatment of gut inflammation is necessary for the rational development of placebo-controlled clinical studies aimed at investigating the efficacy and tolerability of novel PPAR γ agonists in patients with IBD.
In this regard, PPAR γ is widely expressed in all major cell types involved in the immunopathogenesis of IBD, including T cells, macrophages, dendritic cells, endothelial cells and epithelial cells. Previous studies have characterized the impact of the PPAR γ deficiency in epithelial cells in DSS colitis and demonstrated that while PPAR γ expressed in the colonic epithelium has an endogenous role in protection against colitis, rosiglitazone treatment can ameliorate experimental IBD in epithelial cell-specific PPAR γ null mice [
11]. Adding to this story, our laboratory has recently shown that intestinal epithelial cell specific deletion of PPAR γ enhances macrophage MHC II expression in the MLN and lysosomal pathway gene expression in the colon without significantly affecting lymphocyte populations in the blood, spleen, and MLN [
12]. A targeted disruption of PPAR γ in macrophages increased recruitment of macrophages to inflammatory foci in the colon [
13]. This report investigates the role of endogenously activated T cell PPAR γ in experimental IBD.
The initial phases of DSS colitis (i.e., day 2) target the innate components of the immune response (i.e., macrophages and epithelial cells), whereas T cells are recruited at later stages of disease (days 4-7) following the initial epithelial cell damage and macrophage activation. We found that disease activity and body weights were worsened in CD4cre mice at about the fourth day of DSS challenge, indicating that disease progression is accelerated when PPAR γ is absent in T cells. Histologically, colonic inflammatory lesions were limited or null on day 2 whereas significant epithelial erosion and immune cell infiltration was observed on day 7, which was more severe in mice lacking PPAR γ in T cells. Of note, the crosstalk between myeloid cells and lymphocytes represents an important component of disease progression [
38]. CD4
+ T cells and CD4-induced production of IL-6 are both increased in the lamina propria of DSS-treated mice [
39,
40], and the infiltration of CD4
+ T cells into the colon has been shown to correlate with gut immune-mediated pathology [
40].
Transcriptomic profiling of colonic samples revealed that on day 2 of DSS colitis, corresponding to the period of activation of innate immunity, there were 202 genes affected in WT and only 8 genes in CD4cre mice. In contrast, on day 7 when both innate and acquired T cell responses contribute to gut immunopathology, we found a dramatic increase in the number of differentially expressed genes (i.e., 3036) in colons of mice lacking PPAR γ in T cells versus only 39 differentially expressed genes in colons of WT mice. Specifically, on day 7 there were significant increases in IL-6, IL-1β and SOCS3 in colons of CD4cre mice. These proinflammatory cytokines have been shown to accelerate the progression of intestinal inflammation [
41‐
43]. The SOCS3 pathway can be induced by IL-6 and plays a down-regulatory role in the development of intestinal inflammation by inhibiting signal transducer and activator of transcription (STAT3) activation and thereby suppressing expression of inflammatory cytokines [
33]. Since STAT3 is highly tyrosine phosphorylated in UC and CD patients [
33], the upregulation of SOCS3 represents an anti-inflammatory feedback loop. Microarray analysis also revealed a significant increase in genes involved in leukocyte extravasation in the CD4cre mice, a finding that is in line with the increased leukocyte recruitment we observed in colons of T cell-specific PPAR γ null mice. Both VCAM-1 and ICAM-1 are adhesion molecules independently associated with IBD disease severity [
44], and their upregulation is associated with increased NF-κB activity and pro-inflammatory cytokine secretion [
45]. In total, these findings indicate an enhanced pro-inflammatory milieu in colons of CD4cre mice on day 7 of DSS colitis mediated by increased expression of pro-inflammatory cytokines and adhesion molecules.
GSEA of KEGG pathways demonstrated that there was a significant downregulation of gene clusters involved in the maintenance of glucose homeostasis (i.e., Krebs cycle) and protein synthesis (ribosome pathway), but up-regulation of the apoptosis pathway. Together these findings indicate a dysregulated carbohydrate metabolism, suppressed protein translation and altered programmed cell death in colons of CD4cre mice (fold-change in gene expression in Supplementary Table 2). In line with our findings, carbohydrate and amino acid metabolism have recently been shown to be reduced in colons of IBD patients [
46]. Considering that one of the first discovered roles of PPAR γ was the regulation of glucose homeostasis [
47], it is not surprising that the deficiency of PPAR γ in T cells could cause a down-regulation of gene clusters related to Krebs cycle. In turn, these reductions may have also resulted from a generalized increase in the severity of colonic inflammation caused by the deficiency of PPAR γ in T cells, as pro-inflammatory cytokines can inhibit Krebs cycle activity [
48]. The apoptosis and protein synthesis pathways are also largely influenced by inflammation. The apoptosis pathway is critically regulated by NF-κB [
49] which is thought to be repressed by PPAR γ in experimental IBD [
50], and protein synthesis is decreased in the inflamed colon as a result of endoplasmic reticulum (ER) stress and subsequent activation of the unfolded protein response in mouse models of IBD [
51]. Thus, the pathways affected by the deficiency of PPAR γ may be secondary to more severe colitis. ER stress is also associated with induction of apoptosis via activation of an ER resident caspase (caspase-12) [
52]. Further studies are needed to investigate whether T cell PPAR γ regulates mucosal inflammation by altering carbohydrate metabolism, colonic cell apoptosis and protein synthesis and its relation with ER stress.
CD4cre mice have significantly fewer CD4
+FoxP3
+ Tregs in blood and IL10-expressing CD4
+ T cells in the MLN on day 7 of DSS colitis in comparison to WT mice. We have demonstrated that the accumulation of Treg in the mucosal inductive sites (i.e., MLN) is associated with prevention of chronic colitis caused by the adoptive transfer of CD4+CD45RB
hi T cells in SCID mice [
17]. Our flow cytometry results indicate that T cell PPAR γ is required for the maintenance of IL-10-producing CD4
+ T cells in MLN, where intestinal immune responses are regulated, thereby inhibiting IL-6 and IL-1β expression in the gut mucosa during IBD. Specifically, the levels of IL10-expressing CD4+ T cells may be low in CD4Cre mice at the onset due to the lack of PPAR γ. Since regulatory responses are initiated in parallel with inflammatory responses, MLN Tregs are likely to increase in response to the DSS challenge, but their numbers may wane as they are recruited towards the principal site of inflammation; the colonic mucosa.
Adding to what was known about the effect of epithelial cell and macrophage-specific deletion of PPAR γ, our findings indicate that T cell PPAR γ also plays a protective role during the progression of DSS colitis, though to a lesser degree as seen in epithelial cells and macrophages. The lower impact observed with T cell PPAR γ fits with previous findings indicating that epithelial cells and macrophages are the primary inflammatory mediators during acute DSS colitis. Because T cell-mediated inflammation has been shown to be very influential in chronic stages of the disease [
38,
53], it may be worthwhile to assess the affect of T cell PPAR γ in chronic colitis models.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AJG analyzed data, summarized flow cytometry results, performed real-time RT-PCR and contributed to write the manuscript. SKM performed the microarray analyses and contributed to write the manuscript. WTH performed mouse studies and contributed to flow cytometry data acquisition and analysis, and performed RNA isolation. JBR and RH designed the experiments, obtained funding for this project, managed the project and wrote the manuscript.